Hyperargininemia
8
1
2
3
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
25.0%
2 terminated out of 8 trials
60.0%
-26.5% vs benchmark
25%
2 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (8)
Liver Disease in Urea Cycle Disorders
Hepatic Histopathology in Urea Cycle Disorders
Early Check: Expanded Screening in Newborns
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency